论文部分内容阅读
为探讨囊性纤维化跨膜转运调节物 (CysticFibrosisTransmembraneConductanceRegulator,CFTR)基因突变是否影响先天性梗阻性无精子症患者单精子卵浆内注射 (IntracytoplasmicSpermInjection ,ICSI)治疗的成功率 ,本文对3例先天性梗阻性无精子症CFTR突变基因携带者和 18例CFTR突变基因非携带者进行了ICSI的治疗。结果表明 :先天性梗阻性无精子症CFTR突变基因携带者与CFTR突变基因非携带者ICSI治疗时受精率、卵裂率和妊娠率无显著性差异。结论 :CFTR突变基因并不影响先天性梗阻性无精子症患者ICSI治疗的成功率 ,故这些患者在ICSI治疗前夫妻双方更有必要行CFTR突变基因的筛查。
To investigate whether the mutation of cystic fibrosis transmembrane transport regulator (CFTR) affects the success rate of intracytoplasmic sperm injection (ICSI) in patients with congenital obstructive azoospermia, three cases of congenital ICSI was performed on CFTR mutant carriers of obstructive azoospermia and 18 CFTR mutant non-carriers. The results showed that there was no significant difference in fertilization rate, cleavage rate and pregnancy rate between CFTR mutation gene carriers and CFTR mutant non-carrier ICSI patients with congenital obstructive azoospermia. CONCLUSIONS: CFTR mutations do not affect the success rate of ICSI therapy in patients with congenital obstructive azoospermia, and screening of CFTR mutations is even more necessary in these patients before the ICSI treatment.